U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 10 of 10 results

Status:
US Approved Rx (1982)
First approved in 1982

Class (Stereo):
CHEMICAL (ABSOLUTE)



Streptozotocin (Streptozocin, STZ, Zanosar) is a naturally occurring chemical that is particularly toxic to the insulin-producing beta cells of the pancreas in mammals. It is used in medicine for treating certain cancers of the Islets of Langerhans a...
Status:
US Approved Rx (2022)
First approved in 1974

Class (Stereo):
CHEMICAL (ABSOLUTE)



Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...
Status:
US Approved Rx (1982)
First approved in 1982

Class (Stereo):
CHEMICAL (ABSOLUTE)



Streptozotocin (Streptozocin, STZ, Zanosar) is a naturally occurring chemical that is particularly toxic to the insulin-producing beta cells of the pancreas in mammals. It is used in medicine for treating certain cancers of the Islets of Langerhans a...
Status:
US Approved Rx (2022)
First approved in 1974

Class (Stereo):
CHEMICAL (ABSOLUTE)



Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...
Status:
US Approved Rx (2022)
First approved in 1974

Class (Stereo):
CHEMICAL (ABSOLUTE)



Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...
Status:
US Approved Rx (2022)
First approved in 1974

Class (Stereo):
CHEMICAL (ABSOLUTE)



Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...
Status:
US Approved Rx (2022)
First approved in 1974

Class (Stereo):
CHEMICAL (ABSOLUTE)



Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...
Status:
US Approved Rx (2022)
First approved in 1974

Class (Stereo):
CHEMICAL (ABSOLUTE)



Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...
Status:
US Approved Rx (2022)
First approved in 1974

Class (Stereo):
CHEMICAL (ABSOLUTE)



Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...
Status:
US Approved Rx (2022)
First approved in 1974

Class (Stereo):
CHEMICAL (ABSOLUTE)



Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...